Abstract
Monoclonal antibody (MAb) treatments have been safe and effective in averting severe Covid-19 infections when given early, but supplies have been scarce. Intermountain Healthcare used its supply to maximum effect across its broad geographic footprint by identifying patients at highest risk and delivering them MAb therapy at the optimal time, saving lives and easing strain on hospitals.